Clinical Trial: Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies

Brief Summary: This study will determine a dose and schedule for XmAb13676 in the treatment of CD20 expressing hematologic malignancies.

Detailed Summary:
Sponsor: Xencor, Inc.

Current Primary Outcome:

  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: Baseline Day 1 through Day 56 ]
  • Maximum tolerated (MTD) and/or recommended dose (RD) [ Time Frame: Baseline Day 1 through Day 56 ]


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Xencor, Inc.

Dates:
Date Received: September 14, 2016
Date Started: October 2016
Date Completion:
Last Updated: November 21, 2016
Last Verified: November 2016